Literature DB >> 22393644

[Management of high-grade atrioventricular block in Lomé, Togo].

K Yayehd, K Ganou, T Tchamdja, Y Tété, M P N'cho Mottoh, S Pessinaba, F Damorou.   

Abstract

The purpose of this cross-sectional study was to describe epidemiological, clinical and therapeutic aspects of high-grade atrioventricular block in Lomé. Out of 2245 patients hospitalized between June 2004 and May 2009, a total of 22 cases of high-grade atrioventricular block were detected thus a prevalence of 1%. The main symptoms were syncope and presyncope (73%) and dyspnea (50%). There was 77.2% of chronic grade III atrioventricular block and 22.8% of grade II atrioventricular block. A pacemaker has been established in 8 patients (40% of the patients presenting a class I indication) in VVI (R) mode. We noted 59% of deaths among patients who did not benefited from any cardiac pacing.

Entities:  

Mesh:

Year:  2011        PMID: 22393644

Source DB:  PubMed          Journal:  Med Trop (Mars)        ISSN: 0025-682X


  3 in total

1.  Permanent cardiac pacing: first Congolese experiment.

Authors:  Stéphane Méo Ikama; Jospin Makani; Xavier Jouven; Gisèle Kimbally-Kaky
Journal:  Pan Afr Med J       Date:  2015-04-16

2.  Statistics on the use of cardiac electronic devices and interventional electrophysiological procedures in Africa from 2011 to 2016: report of the Pan African Society of Cardiology (PASCAR) Cardiac Arrhythmias and Pacing Task Forces.

Authors:  Aimé Bonny; Marcus Ngantcha; Mohamed Jeilan; Emmy Okello; Bundhoo Kaviraj; Mohammed A Talle; George Nel; Eloi Marijon; Mahmoud U Sani; Zaheer Yousef; Kamilu M Karaye; Ibrahim A Touré; Mohamed A Awad; George Millogo; Jonas Kologo; Adama Kane; Romain Houndolo; Anastase Dzudié; Amam Mbakwem; Bongani M Mayosi; Ashley Chin
Journal:  Europace       Date:  2018-09-01       Impact factor: 5.214

3.  Follow up in a developing country of patients with complete atrio-ventricular block.

Authors:  J C Tantchou Tchoumi; S Foresti; P Lupo; R Cappato; G Butera
Journal:  Cardiovasc J Afr       Date:  2012-11       Impact factor: 1.167

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.